Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenesis and management of cancer associated hypercalcaemia

S H Ralston1

  • 1Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill.

Cancer Surveys
|January 1, 1994
PubMed
Summary

Cancer-associated hypercalcaemia, a common complication, is primarily caused by tumor-released mediators like parathyroid hormone-related protein (PTHrP). Treatment focuses on hydration, bisphosphonates, and calcitonin for symptom relief and improved patient discharge.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Anti-rheumatic Drugs on the Skeleton.

Calcified tissue international·2022
Same author

Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland.

Scandinavian journal of rheumatology·2022
Same author

Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance.

Calcified tissue international·2021
Same author

Rheumatology in a time of Coronavirus: lessons from our early experiences.

QJM : monthly journal of the Association of Physicians·2020
Same author

Cognitive function, disease burden and the structural connectome in systemic lupus erythematosus.

Lupus·2018
Same author

High mortality in younger patients with major osteoporotic fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2016

Area of Science:

  • Oncology
  • Endocrinology
  • Metabolic Complications

Background:

  • Hypercalcaemia is a frequent metabolic complication in cancer patients, significantly contributing to morbidity.
  • It's typically caused by tumor-secreted humoral factors, not bone metastases.
  • Parathyroid hormone-related protein (PTHrP) is a key mediator, mimicking parathyroid hormone (PTH).

Purpose of the Study:

  • To review the causes and management of cancer-associated hypercalcaemia.
  • To highlight the role of palliative anti-hypercalcaemic therapy in improving patient symptoms.

Main Methods:

  • Review of existing literature on hypercalcaemia in malignancy.
  • Discussion of therapeutic strategies including fluid resuscitation, bisphosphonates, gallium nitrate, and calcitonin.

Main Results:

  • Bisphosphonates are effective and well-tolerated agents for inhibiting bone resorption.
  • Combination therapy with bisphosphonates and calcitonin offers rapid serum calcium reduction in severe cases.
  • Effective long-term control relies on treating the primary tumor, which is often not feasible.

Conclusions:

  • Anti-hypercalcaemic therapy is a crucial palliative measure for symptomatic cancer patients.
  • While not altering long-term prognosis, treatment improves symptoms, enabling hospital discharge for many.

Related Experiment Videos